Chronic cough impacts up to 10% of the adult population and has a physical, psychological, and social impact on patients’ lives.

Farrell Simon, chief commercial officer at Trevi Therapeutics, joins web editor Nicole Raleigh on the pharmaphorum podcast to discuss prioritising patients in clinical and commercial development, with an especial focus on chronic cough.

There are currently no approved therapies in either the US or the UK for what is a highly disruptive affliction, accompanied by a wide range of complications, which causes a significant burden on patients, caregivers, and healthcare systems.

Also discussing Trevi’s own work in the field, in particular a potential treatment for idiopathic pulmonary fibrosis (IPF), the conversation explores how to work more closely and holistically with patients in clinical development. Integrating the patient voice is, as Simon says, critical in clinical trial design. After all, the patient is the utmost stakeholder.